The HIFUB study (HIFU in Breast cancer)

  • Research type

    Research Study

  • Full title

    Study of High Intensity Focused Ultrasound (HIFU) in the Treatment of Early Breast Cancer

  • IRAS ID

    233756

  • Contact name

    Gurdeep S. Mannu

  • Contact email

    gurdeep.mannu@ndph.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Clinicaltrials.gov Identifier

    NCT05350059

  • Duration of Study in the UK

    1 years, 9 months, 0 days

  • Research summary

    High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating (destroying) them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). We aim to assess the efficacy and safety of HIFU in the treatment of IBC.

    In this feasibility study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed and correlated with radiological findings from Magnetic Resonance Imaging (MRI) scans. Blood tests investigating immune response will be obtained before and following HIFU treatment. Participant experience of HIFU treatment will be evaluated using a validated patient reported outcome measures questionnaire. This study will not significantly delay the participant’s cancer treatment or influence adjuvant therapy.

    If this study can show that HIFU is safe and effective, it could help lay the foundation for further research to establish a new, non-surgical treatment modality for women with early breast cancer in the UK, that avoids the need for a general anaesthetic or a cut in the skin.

  • REC name

    South Central - Oxford A Research Ethics Committee

  • REC reference

    18/SC/0083

  • Date of REC Opinion

    26 May 2020

  • REC opinion

    Further Information Favourable Opinion